A research study in Uganda to test an intervention called DIALOG+, designed to improve care for people living in the community with severe mental illness

Testing the effectiveness, acceptability and feasibility of DIALOG+ in severe mental illness in Uganda: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN25146122

Enrollment

168

Registered

2018-11-20

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental, neurological and substance misuse disorders, which includes severe mental illness (psychosis, severe depression and anxiety), epilepsy and comorbid substance misuse Mental and Behavioural Disorders

Interventions

14 clinicians will be recruited. For each clinician, the research team will recruit 12 of their patients and then each clinician-patient cluster will be randomly allocated to active control or interve

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Primary diagnosis of severe mental illness (psychosis, bipolar disorder, psychotic/severe depression), epilepsy and/or co-morbid substance misuse, assessed by the ICD-10 2. Attending the outpatient clinic at Butabika, or surrounding clinics in Kampala for at least six months 3. Live within a 20km radius of Kampala city/or the clinic where recruitment will take place 4. Aged 18-65 years old 5. Capacity to provide informed consent assessed by UBACC Score of =14 after a maximum of 3 attempts 6. Scores 5 or below on the MANSA scale 7. Able to communicate in Luganda or English

Exclusion criteria

Exclusion criteria: 1. Primary diagnosis of substance-use disorder; organic psychosis and/or neurocognitive disorder 2. Currently an inpatient at the time of recruitment 3. Already participating in the DIALOG+ study at another clinic or another study organised by this research group 4. Participating in another interventional study taking place at Butabika hospital

Design outcomes

Primary

Measure	Time frame
Quality of life, measured using the Manchester Short Assessment of Quality of Life (MANSA), collected by masked researchers using a case report form as part of a research assessment at baseline, 6 months and 12 months	—

Secondary

Measure	Time frame
Measured at baseline, 6 months (post intervention) and 12 months: 1. Objective social functioning, measured using the Objective social outcome index (SIX) 2. Symptoms, measured using the Brief Psychiatric Rating Scale (BPRS) 3. Stigma, measured using the Internalised Stigma of Mental Illness Inventory (ISMI) 4. Adherence to medication, measured using the Medication Adherence Rating Scale (MARS) 5. Service use, measured using adapted Client Service Receipt Inventory (CSRI)	—

Measure

Time frame

Measured at baseline, 6 months (post intervention) and 12 months: 1. Objective social functioning, measured using the Objective social outcome index (SIX) 2. Symptoms, measured using the Brief Psychiatric Rating Scale (BPRS) 3. Stigma, measured using the Internalised Stigma of Mental Illness Inventory (ISMI) 4. Adherence to medication, measured using the Medication Adherence Rating Scale (MARS) 5. Service use, measured using adapted Client Service Receipt Inventory (CSRI)

—

Countries

Uganda

Contacts

Public ContactFrancois van Loggerenberg

f.vanloggerenberg@qmul.ac.uk+44 (0)20 7540 4380 Ext: 2339

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 2, 2026